Tempus AI Acquires Paige for $81.25 Million

Tempus AI to Acquire Personalis for $1.5 Billion to Expand MRD Precision Oncology Monitoring

July 21, 2026

Healthcare Services

Tempus AI has entered into a definitive agreement to acquire Personalis in a transaction with an enterprise value of approximately $1.5 billion (net of Tempus’ existing stake). Personalis shareholders will receive $16.25 per share, with consideration primarily structured as Tempus stock and Tempus having the option to pay up to 50% in cash. The deal is expected to close in late 2026 or early 2027, subject to shareholder approval, regulatory clearances, and customary closing conditions.

Roche to Acquire PathAI to Expand AI-Powered Digital Pathology

May 7, 2026

AI & Machine Learning

Roche has entered into a definitive merger agreement to acquire PathAI, a US digital pathology and AI technology company. The deal is expected to close in the second half of the year and will integrate PathAI’s AISight image management system into Roche’s Diagnostics division.

Standard AI Acquires Pathr.ai

January 9, 2026

AI & Machine Learning

Standard AI has acquired Pathr.ai, a spatial intelligence startup that analyzes in-store movement and behavior, bringing Pathr.ai’s founder and several team members into Standard AI’s engineering organization. The deal expands Standard AI’s computer-vision and spatial analytics capabilities to accelerate enterprise retail deployments and global expansion.

Tempus Acquires Deep 6 AI

March 11, 2025

Healthcare Services

Tempus AI, Inc. (NASDAQ: TEM) has acquired Deep 6 AI, an AI-powered precision research platform that matches patients to clinical trials by mining structured and unstructured EMR data. The acquisition expands Tempus' provider network (Deep 6 is integrated with 750+ provider sites covering more than 30 million patients) and enhances Tempus' clinical-trial matching and real-world evidence capabilities to accelerate recruitment and RWE generation.

Tempus Acquires Highline Sciences

February 8, 2022

Healthcare Services

Tempus, the Chicago-based AI-driven precision medicine company, has acquired Highline Sciences, a San Francisco-based full-service clinical CRO focused on oncology. The acquisition will allow Tempus to vertically integrate additional clinical trial services and expand its capabilities to support and grow clinical research offerings for oncology therapeutics.

PNC Bank Acquires Tempus Technologies, Inc.

January 27, 2021

Financial Services

PNC Bank N.A. reached a definitive agreement to acquire Tempus Technologies, Inc., a payment gateway and payments-processing solutions provider. The acquisition will expand PNC Treasury Management's payments capabilities by integrating Tempus' gateway, mobile apps and payment portals to support multiple payment rails.